Dermatomyositis treatment market seen topping $1 billion by 2030

By AI, Created 5:17 PM UTC, May 18, 2026, /AGP/ – The Business Research Company projects the global dermatomyositis treatment market will exceed $1 billion by 2030, led by North America and the U.S. The report points to rising autoimmune disease prevalence, broader access to biologics and earlier diagnosis as the main growth drivers.

Why it matters: - Dermatomyositis treatment is moving from a niche rare-disease market to a larger commercial opportunity. - The market is projected to top $1 billion by 2030, with demand concentrated in regions that have stronger specialty care access and higher diagnosis rates. - The forecast signals continued growth in biologics, immunotherapies and other targeted therapies used for chronic autoimmune care.

What happened: - The Business Research Company released a market forecast for dermatomyositis treatment through 2030. - The report projects the global market will surpass $1 billion by 2030. - The market is expected to grow at a 7% CAGR leading up to 2030. - North America is forecast to be the largest region in 2030, with a market value of $0.45 billion. - The U.S. is projected to be the largest country in the market in 2030, at $0.37 billion. - The full report is available online.

The details: - North America is expected to grow from $0.32 billion in 2025 to $0.45 billion in 2030, a 7% CAGR. - The U.S. market is expected to rise from $0.27 billion in 2025 to $0.37 billion in 2030, a 6% CAGR. - The report ties North American growth to advanced healthcare infrastructure, higher diagnosis rates, greater access to specialty care and biologic therapies, rising healthcare spending and active drug development. - The report links U.S. growth to reimbursement coverage, clinical research activity, early adoption of advanced biologics and combination therapies, specialty clinic density and personalized medicine innovation. - The market is segmented by treatment type, route of administration, patient demographics, distribution channel and end user. - Treatment types include pharmacological treatments, immunosuppressants, corticosteroids, biologics and physical therapy. - Oral, intravenous and subcutaneous are listed as route-of-administration segments. - Age group and gender are listed as patient-demographic segments. - Hospital pharmacy, online pharmacy and retail pharmacy are listed as distribution channels. - Hospitals, homecare, specialty clinics and other end users are listed as end-user segments. - Pharmacological treatments are projected to be the largest treatment-type segment in 2030, accounting for 43% of the market, or $0.5 billion. - Pharmacological treatments are expected to be supported by first-line drug use, combination regimens, targeted biologics, non-invasive care preferences and improved drug formulation. - The report says the most significant growth opportunities are expected in pharmacological treatments, immunosuppressants, corticosteroids, biologics and physical therapy. - Those segments are projected to add more than $0.4 billion in market value by 2030. - Over the next five years, pharmacological treatments, immunosuppressants, corticosteroids and physical therapy are each projected to grow by $0.1 billion, while biologics are projected to grow by $0.03 billion. - The broader parent market, neurology devices, is expected to reach about $36 billion by 2030. - Dermatomyositis treatment is forecast to represent around 3% of that parent market. - Within the broader medical equipment industry, projected at $1,176 billion by 2030, dermatomyositis treatment is expected to account for nearly 0.1% of total market value. - The company announcement offers a sample request page for the report.

Between the lines: - The forecast suggests rare-disease treatment markets can scale quickly when diagnosis improves and specialty therapies expand. - The report’s biggest growth drivers are not new patient categories, but better recognition of autoimmune disease, more advanced biologics and wider awareness of rare conditions. - The emphasis on pharmacological treatments shows that drug-based care remains the core commercial center of the market, even as supportive therapies gain traction.

What’s next: - The report expects growth to stay tied to biologic innovation, early diagnosis and broader access to specialty care through 2030. - Market expansion will likely continue to favor regions with stronger reimbursement systems, research activity and specialty infrastructure. - The treatment mix may keep shifting toward targeted therapies and combination regimens as clinical practice evolves.